Maintaining Investments in New Innovation Act

This bill, called the Maintaining Investments in New Innovation Act, changes when certain new drugs can have their prices negotiated by Medicare. It says that if a drug uses “genetically targeted technology,” Medicare cannot start negotiating its price until the drug has been on the market for at least 11 years. Today, Medicare’s negotiation program generally starts after 7 years for many drugs and 11 years for biologics, with negotiations beginning in 2026. This bill would move genetically targeted drugs into the 11‑year timeline before Medicare can negotiate their prices .

What this means: some high‑tech, gene‑focused medicines would have a longer period before Medicare can try to lower their prices through negotiation. The bill’s stated goal is to protect access to genetically targeted technologies.

Key points

• Who is affected: People on Medicare who use genetically targeted drugs, and the companies that make those drugs.
• What changes: Medicare would wait 11 years, not 7, before negotiating prices for these drugs; biologics already have an 11‑year wait.
• When: Medicare’s negotiation program begins in 2026; this bill adjusts which drugs qualify and when.